Journal Article

Determining the impact of Benzathine penicillin G prophylaxis in children with latent rheumatic heart disease (GOAL trial): Study protocol for a randomized controlled trial

DeWyer, Alyssa, Beaton, Andrea, Okello, Emmy, Rwebembera, Joselyn, Grobler, Anneke, Sarnacki, Rachel, Scheel, Amy, Steer, Andrew, Engelman, Daniel, Sable, Craig, Omara, Isaac Otim

2019

Overview

Rheumatic heart disease (RHD) remains a high prevalence condition in low- and middle-income countries. Most individuals with RHD present late, missing the opportunity to benefit from secondary antibiotic prophylaxis. Echocardiographic screening can detect latent RHD, but the impact of secondary prophylaxis in screen-detected individuals is not known. This trial aims to determine if secondary prophylaxis with every-4-week injectable Benzathine penicillin G (BPG) improves outcomes for children diagnosed with latent RHD. This is a randomized controlled trial in consenting children, aged 5 to 17 years in Northern Uganda, confirmed to have borderline RHD or mild definite RHD on echocardiography, according to the 2012 World Heart Federation criteria. Qualifying children will be randomized to every-4-week injectable intramuscular BPG or no medical intervention and followed for a period of 2 years. Ongoing intervention adherence and retention in the trial will be supported through the establishment of peer support groups for participants in the intervention and control arms. A blinded echocardiography adjudication panel consisting of four independent experts will determine the echocardiographic classification at enrollment and trajectory through consensus review. The primary outcome is the proportion of children in the BPG-arm who demonstrate echocardiographic progression of latent RHD compared to those in the control arm. The secondary outcome is the proportion of children in the BPG-arm who demonstrate echocardiographic regression of latent RHD compared to those in the control arm. A sample size of 916 participants will provide 90% power to detect a 50% relative risk reduction assuming a 15% progression in the control group. The planned study duration is from 2018–2021. Policy decisions on the role of echocardiographic screening for RHD have stalled because of the lack of evidence of the benefit of secondary prophylaxis. The results of our study will immediately inform the standard of care for children diagnosed with latent RHD and will shape, over 2–3 years, practical and scalable programs that could substantially decrease the burden of RHD in our lifetime. ClinicalTrials.gov: NCT03346525. Date Registered: November 17, 2017.

• Publisher: Elsevier Inc,Elsevier Limited
• Subject: Adjudication / Adolescent / Anti-Bacterial Agents - administration & dosage / Anti-Bacterial Agents - therapeutic use / Antibiotics / Cardiovascular disease / Cardiovascular diseases / Child / Child, Preschool / Children / Clinical trials / Clinical Trials, Phase III as Topic / Coronary artery disease / Data collection / Disease control / Disease prevention / Disease Progression / Drug Administration Schedule / Echocardiography / Families & family life / Heart / Heart diseases / Humans / Intervention / Morphology / Outcome Assessment, Health Care / Penicillin / Penicillin G Benzathine - administration & dosage / Penicillin G Benzathine - therapeutic use / Randomization / Randomized Controlled Trials as Topic / Rheumatic fever / Rheumatic heart disease / Rheumatic Heart Disease - diagnostic imaging / Rheumatic Heart Disease - drug therapy / Rheumatic Heart Disease - microbiology / Rheumatic Heart Disease - prevention & control / Risk management / Screening / Secondary Prevention - methods / Uganda / Ultrasonic imaging